Geneva, Aug. 31 -- International Clinical Trials Registry received information related to the study (NCT07775313) titled 'Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM' on Aug. 19.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Condition:
WHIM
Warts
Hypogammaglobulinemia
Immunodeficiency
Myelokathexis
Intervention:
Drug: Busulfan
Drug: Palifermin
Drug: Plerixafor
Drug: Filgrastim
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: August 26, 2026
Target Sample Siz...